Table 3.
Summary of efficacy results
| Fremanezumab | ||||||
|---|---|---|---|---|---|---|
| n | Monthly | n | Quarterly | |||
| Actual | Change from baseline | Actual | Change from baseline | |||
| Average monthly migraine days, mean (SD) | ||||||
| Baseline | 25 | 14.1 (5.6) | 25 | 13.8 (5.5) | ||
| Month 1 | 25 | 10.0 (7.0) | − 4.1 (5.5) | 25 | 9.5 (6.4) | − 4.2 (5.3) |
| Month 3 | 25 | 12.0 (7.3) | − 2.1 (5.5) | 25 | 11.7 (7.0) | − 2.1 (6.5) |
| Month 6 | 24 | 11.3 (6.6) | − 2.9 (4.9) | 23 | 10.7 (6.4) | − 3.3 (4.2) |
| Month 12 | 23 | 8.5 (5.6) | − 5.9 (4.3) | 22 | 12.4 (7.0) | − 1.6 (5.7) |
| Average monthly headache days of at least moderate severity, mean (SD) | ||||||
| Baseline | 25 | 11.8 (5.8) | 25 | 12.8 (6.7) | ||
| Month 1 | 25 | 8.2 (6.0) | − 3.6 (4.9) | 25 | 8.1 (6.7) | − 4.7 (4.6) |
| Month 3 | 25 | 9.9 (6.9) | − 2.0 (5.2) | 25 | 10.1 (7.7) | − 2.7 (6.1) |
| Month 6 | 24 | 9.8 (6.2) | − 2.1 (4.2) | 23 | 10.1 (7.2) | − 3.2 (4.2) |
| Month 12 | 23 | 8.0 (5.4) | − 4.3 (4.1) | 22 | 11.0 (7.4) | − 2.1 (4.1) |
| Average monthly headache days at any severity, mean (SD) | ||||||
| Baseline | 25 | 13.8 (6.6) | 25 | 14.1 (7.3) | ||
| Month 1 | 25 | 9.8 (7.5) | − 4.0 (5.7) | 25 | 9.2 (7.0) | − 4.9 (4.5) |
| Month 3 | 25 | 11.2 (7.4) | − 2.6 (5.3) | 25 | 11.2 (8.1) | − 2.8 (5.8) |
| Month 6 | 24 | 10.8 (6.9) | − 3.2 (4.7) | 23 | 11.0 (7.2) | − 3.7 (4.1) |
| Month 12 | 23 | 8.5 (5.5) | − 5.8 (4.4) | 22 | 12.2 (7.1) | − 2.3 (4.9) |
| Average monthly days with use of any acute headache medication, mean (SD) | ||||||
| Baseline | 25 | 13.7 (6.8) | 25 | 13.8 (6.6) | ||
| Month 1 | 25 | 10.3 (7.3) | − 3.4 (5.1) | 25 | 9.0 (5.9) | − 4.8 (5.1) |
| Month 3 | 25 | 11.0 (6.6) | − 2.7 (6.3) | 25 | 11.2 (7.3) | − 2.6 (5.8) |
| Month 6 | 24 | 12.0 (7.1) | − 1.9 (5.6) | 23 | 11.5 (6.6) | − 2.8 (4.0) |
| Month 12 | 23 | 9.5 (6.1) | − 4.5 (5.6) | 22 | 11.8 (5.4) | − 2.3 (4.6) |
| Average monthly days with nausea or vomiting, mean (SD) | ||||||
| Baseline | 25 | 5.2 (5.5) | 25 | 3.7 (3.5) | ||
| Month 1 | 25 | 3.5 (5.8) | − 1.7 (2.6) | 25 | 2.3 (2.9) | − 1.4 (3.0) |
| Month 3 | 25 | 4.4 (6.0) | − 0.8 (5.1) | 25 | 3.4 (4.6) | − 0.3 (3.1) |
| Month 6 | 24 | 3.4 (4.6) | − 1.9 (4.8) | 23 | 2.3 (3.2) | − 1.7 (3.5) |
| Month 12 | 23 | 2.2 (3.1) | − 3.2 (4.4) | 22 | 3.7 (4.3) | − 0.4 (4.5) |
| Average monthly days with photophobia and phonophobia, mean (SD) | ||||||
| Baseline | 25 | 6.5 (6.8) | 25 | 5.3 (6.4) | ||
| Month 1 | 25 | 5.6 (7.7) | − 1.0 (4.3) | 25 | 4.2 (6.7) | − 1.1 (4.8) |
| Month 3 | 25 | 6.5 (7.9) | 0.0 (4.6) | 25 | 4.4 (7.3) | − 0.9 (6.2) |
| Month 6 | 24 | 5.7 (7.2) | − 0.8 (4.8) | 23 | 4.0 (6.3) | − 1.5 (4.6) |
| Month 12 | 23 | 3.5 (4.0) | − 3.1 (4.3) | 22 | 5.1 (7.1) | − 0.6 (6.2) |
SD standard deviation